A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen

NCT00932373 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
54
Enrollment
INDUSTRY
Sponsor class

Conditions

Interventions

Sponsor

Genentech, Inc.